Shopping Cart 0
Cart Subtotal
AED 0

Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020

Details

Amyotrophic Lateral Sclerosis-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis-Pipeline Review, H2 2018, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape.

Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Amyotrophic Lateral Sclerosis-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 6, 25, 16, 2, 89, 26 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 32 and 10 molecules, respectively.

Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 7

Amyotrophic Lateral Sclerosis-Overview 8

Amyotrophic Lateral Sclerosis-Therapeutics Development 9

Amyotrophic Lateral Sclerosis-Therapeutics Assessment 33

Amyotrophic Lateral Sclerosis-Companies Involved in Therapeutics Development 49

Amyotrophic Lateral Sclerosis-Drug Profiles 90

Amyotrophic Lateral Sclerosis-Dormant Projects 506

Amyotrophic Lateral Sclerosis-Discontinued Products 516

Amyotrophic Lateral Sclerosis-Product Development Milestones 518

Appendix 529


List Of Figure

List of Figures

Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by AB Science SA, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Acceleron Pharma Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Affichem SA, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Alexion Pharmaceuticals Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Anavex Life Sciences Corp, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Apogenix AG, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Apotex Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Aquestive Therapeutics Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by ArmaGen Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Avanir Pharmaceuticals Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by AveXis Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Axovant Sciences Ltd, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Bactevo Ltd, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Bausch Health Companies Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by BioElectron Technology Corp, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Biogen Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by BioHealthonomics Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by BrainStorm Cell Therapeutics Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Calico LLC, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by CerSci Therapeutics Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Chronos Therapeutics Ltd, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Corcept Therapeutics Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Corestem Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by CSPC NBP Pharmaceutical Co Ltd, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Cytokinetics Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Denali Therapeutics Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Disarm Therapeutics Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Eisai Co Ltd, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Emerald Health Sciences Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by FPRT Bio Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Gemac SA, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Genentech Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Genervon Biopharmaceuticals LLC, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by GeNeuro SA, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Gilead Sciences Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Glialogix Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Grifols SA, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Amyotrophic Lateral Sclerosis Therapeutic Products under Development, Key Players in Amyotrophic Lateral Sclerosis Therapeutics, Amyotrophic Lateral Sclerosis Pipeline Overview, Amyotrophic Lateral Sclerosis Pipeline, Amyotrophic Lateral Sclerosis Pipeline Assessment


Companies

AB Science SA

Acceleron Pharma Inc

Affichem SA

Alexion Pharmaceuticals Inc

Anavex Life Sciences Corp

Apogenix AG

Apotex Inc

Aquestive Therapeutics Inc

ArmaGen Inc

Avanir Pharmaceuticals Inc

AveXis Inc

Axovant Sciences Ltd

Bactevo Ltd

Bausch Health Companies Inc

BioElectron Technology Corp

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

BioHealthonomics Inc

BrainStorm Cell Therapeutics Inc

Calico LLC

CerSci Therapeutics Inc

Chronos Therapeutics Ltd

Chugai Pharmaceutical Co Ltd

Corcept Therapeutics Inc

Corestem Inc

CSPC NBP Pharmaceutical Co Ltd

Cytokinetics Inc

Denali Therapeutics Inc

Disarm Therapeutics Inc

Eisai Co Ltd

Emerald Health Sciences Inc

FPRT Bio Inc

Gemac SA

Genentech Inc

Genervon Biopharmaceuticals LLC

GeNeuro SA

Gilead Sciences Inc

Glialogix Inc

Grifols SA

Hemostemix Inc

Herantis Pharma Plc

InFlectis BioScience

Ionis Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

K-Pax Pharmaceuticals Inc

Kadimastem Ltd

KineMed Inc

Kringle Pharma Inc

Kyorin Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

M3 Biotechnology Inc

Maas Biolab

MallInckrodt Plc

MedDay SA

MeiraGTx Holdings Plc

MimeTech Srl

Miragen Therapeutics Inc

Mitsubishi Tanabe Pharma Corp

NeuCyte Inc

Neuralstem Inc

Neurimmune Holding AG

Neurodyn Life Sciences Inc

Neurofx Inc

NeuroSense Therapeutics Ltd

Neurotune AG

New Biotic Inc

Orion Corp

Orphazyme A/S

Oxford BioMedica Plc

Pfizer Inc

Pharnext SA

Plex Pharmaceuticals Inc

Priavoid GmbH

ProMIS Neurosciences Inc

Prosetta Biosciences Inc

Prothena Corp Plc

QurAlis Corp

Relmada Therapeutics Inc

reMYND NV

Revalesio Corp

Sangamo Therapeutics Inc

Teva Pharmaceutical Industries Ltd

TikoMed AB

Tiziana Life Sciences Plc

Treeway BV

Ultragenyx Pharmaceutical Inc

Verge Genomics Inc

ViroMed Co Ltd

Voyager Therapeutics Inc

WAVE Life Sciences Ltd

Yooyoung Pharm Co Ltd

ZZ Biotech LLC

Company Profile

Company Profile Title

Amyotrophic Lateral Sclerosis-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis-Pipeline Review, H2 2018, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape.

Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Amyotrophic Lateral Sclerosis-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 6, 25, 16, 2, 89, 26 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 32 and 10 molecules, respectively.

Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 7

Amyotrophic Lateral Sclerosis-Overview 8

Amyotrophic Lateral Sclerosis-Therapeutics Development 9

Amyotrophic Lateral Sclerosis-Therapeutics Assessment 33

Amyotrophic Lateral Sclerosis-Companies Involved in Therapeutics Development 49

Amyotrophic Lateral Sclerosis-Drug Profiles 90

Amyotrophic Lateral Sclerosis-Dormant Projects 506

Amyotrophic Lateral Sclerosis-Discontinued Products 516

Amyotrophic Lateral Sclerosis-Product Development Milestones 518

Appendix 529


List Of Figure

List of Figures

Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by AB Science SA, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Acceleron Pharma Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Affichem SA, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Alexion Pharmaceuticals Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Anavex Life Sciences Corp, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Apogenix AG, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Apotex Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Aquestive Therapeutics Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by ArmaGen Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Avanir Pharmaceuticals Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by AveXis Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Axovant Sciences Ltd, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Bactevo Ltd, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Bausch Health Companies Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by BioElectron Technology Corp, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Biogen Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by BioHealthonomics Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by BrainStorm Cell Therapeutics Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Calico LLC, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by CerSci Therapeutics Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Chronos Therapeutics Ltd, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Corcept Therapeutics Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Corestem Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by CSPC NBP Pharmaceutical Co Ltd, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Cytokinetics Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Denali Therapeutics Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Disarm Therapeutics Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Eisai Co Ltd, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Emerald Health Sciences Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by FPRT Bio Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Gemac SA, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Genentech Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Genervon Biopharmaceuticals LLC, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by GeNeuro SA, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Gilead Sciences Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Glialogix Inc, H2 2018

Amyotrophic Lateral Sclerosis-Pipeline by Grifols SA, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Amyotrophic Lateral Sclerosis Therapeutic Products under Development, Key Players in Amyotrophic Lateral Sclerosis Therapeutics, Amyotrophic Lateral Sclerosis Pipeline Overview, Amyotrophic Lateral Sclerosis Pipeline, Amyotrophic Lateral Sclerosis Pipeline Assessment


Companies

AB Science SA

Acceleron Pharma Inc

Affichem SA

Alexion Pharmaceuticals Inc

Anavex Life Sciences Corp

Apogenix AG

Apotex Inc

Aquestive Therapeutics Inc

ArmaGen Inc

Avanir Pharmaceuticals Inc

AveXis Inc

Axovant Sciences Ltd

Bactevo Ltd

Bausch Health Companies Inc

BioElectron Technology Corp

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

BioHealthonomics Inc

BrainStorm Cell Therapeutics Inc

Calico LLC

CerSci Therapeutics Inc

Chronos Therapeutics Ltd

Chugai Pharmaceutical Co Ltd

Corcept Therapeutics Inc

Corestem Inc

CSPC NBP Pharmaceutical Co Ltd

Cytokinetics Inc

Denali Therapeutics Inc

Disarm Therapeutics Inc

Eisai Co Ltd

Emerald Health Sciences Inc

FPRT Bio Inc

Gemac SA

Genentech Inc

Genervon Biopharmaceuticals LLC

GeNeuro SA

Gilead Sciences Inc

Glialogix Inc

Grifols SA

Hemostemix Inc

Herantis Pharma Plc

InFlectis BioScience

Ionis Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

K-Pax Pharmaceuticals Inc

Kadimastem Ltd

KineMed Inc

Kringle Pharma Inc

Kyorin Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

M3 Biotechnology Inc

Maas Biolab

MallInckrodt Plc

MedDay SA

MeiraGTx Holdings Plc

MimeTech Srl

Miragen Therapeutics Inc

Mitsubishi Tanabe Pharma Corp

NeuCyte Inc

Neuralstem Inc

Neurimmune Holding AG

Neurodyn Life Sciences Inc

Neurofx Inc

NeuroSense Therapeutics Ltd

Neurotune AG

New Biotic Inc

Orion Corp

Orphazyme A/S

Oxford BioMedica Plc

Pfizer Inc

Pharnext SA

Plex Pharmaceuticals Inc

Priavoid GmbH

ProMIS Neurosciences Inc

Prosetta Biosciences Inc

Prothena Corp Plc

QurAlis Corp

Relmada Therapeutics Inc

reMYND NV

Revalesio Corp

Sangamo Therapeutics Inc

Teva Pharmaceutical Industries Ltd

TikoMed AB

Tiziana Life Sciences Plc

Treeway BV

Ultragenyx Pharmaceutical Inc

Verge Genomics Inc

ViroMed Co Ltd

Voyager Therapeutics Inc

WAVE Life Sciences Ltd

Yooyoung Pharm Co Ltd

ZZ Biotech LLC